Best in Biotech 28 Oct 2025 The 11 most advanced microbiome players aiming for the gut Take a look at 11 of the top biotech companies working on the development of gut microbiome therapies to treat a range of diseases. October 28, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 3 Feb 2023Beyond Biotech podcast 32: Cancer Research Horizons, Enterome, OncoHost, TrakCel, Turbine Our guests are Ofer Sharon, CEO of OncoHost; Matthew Lakelin, co-founder, TrakCel; Pierre Belichard, CEO of Enterome; and Tony Hickson, chief business officer for Cancer Research UK and Cancer Research Horizons and Daniel Veres, chief science officer and co-founder, Turbine. World Cancer Day February 4 is World Cancer Day. This year, the theme is Close […] February 3, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022 Enterome completes patient enrollment for recurrent glioblastoma study Enterome has completed patient enrollment in its phase 2 clinical trial (ROSALIE) evaluating its lead OncoMimics candidate, EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy (bevacizumab) in patients with first progression/recurrence of glioblastoma, an aggressive form of brain cancer. Enterome is a French clinical stage company developing first-in-class immunomodulatory drugs […] December 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Nov 2022 Get to know 15 of the best biotech companies in Paris Paris may attract tourist masses, but it also attracts a lot of biotech enthusiasts. In this guide, we explore 15 interesting biotech companies in Paris. Paris is one of the biggest biotech clusters in Europe, with a wide range of applications being developed from drug discovery and medical devices to synthetic biology and green energy. […] November 4, 2022 - 11 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Enterome presents more data on therapeutic cancer treatment Clinical stage biopharma company Enterome has presented new data from its two phase 1/2 clinical trials of its OncoMimics cancer immunotherapy EO2401. The trails are in combination with nivolumab (Opdivo) +/- bevacizumab (Avastin), in patients with first progression/recurrence of glioblastoma (ROSALIE trial), and in combination with nivolumab in patients with non-resectable adrenocortical carcinomas (ACC) and […] September 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2020 Enterome Secures €46M to Take Microbiome Therapies to Clinical Trials French microbiome biotech Enterome has raised €46.3M in Series E funding to progress its cancer and inflammatory bowel disease therapies to phase I trials in a few weeks. Two new investors to Enterome — SymBiosis, a US-based investor, and the Japanese big pharma Takeda — took part in the fundraise in addition to existing investors […] June 29, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 15 Oct 2019 Four New Technologies That Will Change Cancer Treatment New approaches to tame the immune system in the fight against cancer are getting us closer to a future where cancer becomes a curable disease. Personalized vaccines, cell therapy, gene editing and microbiome treatments are four technologies that will change the way cancer is treated. Curing cancer is certainly one of the big challenges of […] October 15, 2019 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Mar 2019 Seventure Continues Microbiome Investment Success with Second Fund After the success of the world’s first fund dedicated to companies in nutrition, digital health, and the microbiome, the French venture capital firm Seventure Partners has completed the first closing of a second microbiome fund, which is expected to total €200M. The fund is the successor to Seventure’s Health for Life Capital fund, which was […] March 5, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 22 Jan 2019 No Guts, No Glory: How Microbiome Research is Changing Medicine Scientists are uncovering many ways that the microorganisms that share our body can influence our health. It appears as though the human microbiome could be the key to treating all sorts of diseases, but how can we make these tiny creatures collaborate with us? Let’s do a gut check. We’ve all been told that our […] January 22, 2019 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2018 Microbiome Biotech Enterome Signs Deal With Takeda Worth up to €600M The French biotech Enterome and Takeda are teaming up to fight Crohn’s disease, with a deal worth up to €600M. The two companies will collaborate in the development and commercialization of Enterome’s lead microbiome-targeting treatment currently in Phase I trials. Under the terms of the deal, Takeda will pay Enterome €44M upfront, and up to […] October 23, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 Enterome Brings in a €32M Series D for its Microbiome-Based Therapies Enterome will use the money to progress two of its leading microbiome programs for the treatment of Crohn’s disease and an aggressive form of brain cancer. Enterome is a pioneer in the exciting field of microbiome-based therapies for diseases like inflammatory bowel diseases and cancer. This morning, the company has announced that it has raised €32M in […] January 4, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2017 Enterome and Nestle Launch a New Microbiome Diagnostics Company Microbiome Diagnostics Partners will develop diagnostics tests with Enterome’s microbiome platform IP and a €20M investment from Nestlé. Nestlé Health Science and Enterome have created Microbiome Diagnostics Partners (MDP) as a joint venture split 50% between both parties. Nestlé has invested €20M for its stake in the new company as well as the exclusive option to commercialize […] July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email